Search results for "prednisone"

showing 10 items of 98 documents

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus

2010

Background  One of the major goals of pemphigus therapy is to reduce the patient’s cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. Observations  Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

medicine.medical_specialtybusiness.industryPemphigus vulgarisMycophenolate SodiumAzathioprineDermatologymedicine.diseaseGastroenterologySurgeryPemphigusRefractoryPrednisoneInternal medicinemedicineAdjuvant therapyAdverse effectbusinessmedicine.drugInternational Journal of Dermatology
researchProduct

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet's disease refractory to standard…

2011

Abstract The aim of the study was to assess the long-term efficacy and safety of Infliximab therapy in the treatment of patients with Behçet’s disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg Infliximab (at weeks 0, 2 and 6) and then…

AdultMalemedicine.medical_specialtyAdolescentCyclophosphamideImmunologyAzathioprineBehcet's diseaseRheumatologyPrednisoneInternal medicinemedicineHumansImmunology and AllergyAdverse effectAgedTumor Necrosis Factor-alphabusiness.industryBehcet SyndromeAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabSurgeryDiscontinuationBehçet’s disease - TNF alfa - InfliximabClinical trialTreatment OutcomeAntirheumatic AgentsFemalebusinessmedicine.drug
researchProduct

Antiphospholipid syndrome in obstetrics.

2003

Antiphospholipid syndrome (APLS) in pregnancy is characterized by the presence of autoantibodies in association with recurrent fetal loss and severe complications such as preeclampsia, fetal growth retardation, or placental insufficiency. The most clinically important serologic markers are lupus anticoagulant, anticardiolipin antibodies, and recently anti-beta-2-glycoprotein 1 antibodies. At present, standardization does not exist and a definitive association between specific clinical manifestation and antibody level is not yet known. Experimental data gave evidence that passive transfer of antiphospholipid antibodies result in clinical manifestation of APLS, that is, fetal loss and thromb…

Adultmedicine.medical_specialtyAbortion HabitualPlacental insufficiency030204 cardiovascular system & hematologyGastroenterologyPreeclampsia03 medical and health sciences0302 clinical medicinePre-Eclampsiaimmune system diseasesAntiphospholipid syndromePregnancyInternal medicinemedicinePrevalenceHumansThrombophiliaAnnexin A5030203 arthritis & rheumatologyLupus anticoagulantAspirinPregnancyFetal Growth RetardationAspirinbusiness.industryHeparinStandard treatmentInfant NewbornAnticoagulantsImmunoglobulins IntravenousHematologyGeneral MedicineHeparinmedicine.diseaseAntiphospholipid SyndromePlacental InsufficiencyThrombocytopeniaAbortion SpontaneousPregnancy ComplicationsAntibodies AnticardiolipinLupus Coagulation InhibitorImmunologyPrednisoneFemalebusinessImmunity Maternally-AcquiredImmunosuppressive Agentsmedicine.drugClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
researchProduct

Ciclosporin and thyroid-stimulating immunoglobulins in endocrine orbitopathy.

1989

The study investigated whether ciclosporin (C) affected the thyroid-stimulating immunoglobulins (TSI) in serum of patients with endocrine orbitopathy (EO). The effect of C was compared with that of prednisone (P). Fifteen patients with EO classes III-V received C (n = 7) or P (n = 8). In addition to the immunosuppressants, five patients with Graves' disease in each group received methimazole (MMI). The stimulation of the cAMP levels in the medium of thyrocyte cultures was determined as a parameter of TSI. The TSI levels were markedly lowered in both groups during and after therapy. C group: before therapy 6.2 pmol/ml +/- 1.63 (100%, mean +/- SEM), during treatment 4.6 pmol/ml +/- 2.28 (74%)…

AdultMalemedicine.medical_specialtymedicine.drug_classGraves' diseasemedicine.medical_treatmentThyroid GlandCyclosporinsPrednisoneInternal medicinemedicineCyclic AMPExophthalmosHumansAgedChemotherapyTriiodothyronineMethimazolebusiness.industryThyroidGeneral MedicineMiddle Agedmedicine.diseaseCiclosporinGraves DiseaseTiterEndocrinologymedicine.anatomical_structureImmunoglobulin GCorticosteroidPrednisoneTriiodothyronineFemalebusinessmedicine.drugImmunoglobulins Thyroid-StimulatingResearch in experimental medicine. Zeitschrift fur die gesamte experimentelle Medizin einschliesslich experimenteller Chirurgie
researchProduct

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

2017

Abstract Background Anti-N-methyl-D-aspartate receptor encephalitis is a rare autoimmune disease characterized by severe neurological and psychiatric symptoms and a difficult diagnosis. The disease is often secondary to a neoplastic lesion, seldom diagnosed years later. Psychiatric symptoms are prevalent in adults; neurologic symptoms are more evident in children, who typically present primarily with neurological symptoms. To the best of our knowledge, the association with juvenile idiopathic arthritis has not been described. Case presentation We report the cases of two caucasian girls with an atypical presentation. The first patient was an 8-year-old girl with normal psychomotor developmen…

PediatricsPathologyChoreiform movementAnti-Inflammatory AgentsArthritislcsh:MedicineCase ReportDisease0302 clinical medicinePrednisoneChildOvarian Neoplasms030219 obstetrics & reproductive medicineMedicine (all)Remission InductionTeratomaImmunoglobulins IntravenousGeneral MedicineMagnetic Resonance ImagingTreatment OutcomeMethylprednisoloneFemaleHip JointTeratomamedicine.symptomEncephalitismedicine.drugmedicine.medical_specialtyAdolescentAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Medicine (all)Methylprednisolone03 medical and health sciencesJuvenile idiopathic arthritiChoreaPsychiatric symptomsmedicineHumansImmunologic FactorsAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; TeratomaAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Adolescent; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Arthritis Infectious; Child; Female; Hip Joint; Humans; Immunoglobulins Intravenous; Immunologic Factors; Magnetic Resonance Imaging; Methylprednisolone; Ovarian Neoplasms; Remission Induction; Teratoma; Treatment Outcome; Medicine (all)Speech disorderSpeech disordersArthritis InfectiousPsychiatric symptombusiness.industrylcsh:RChoreaJuvenile idiopathic arthritismedicine.diseaseAnti-N-methyl-D-aspartate receptor encephalitisbusiness030217 neurology & neurosurgeryAnti-N-methyl-D-aspartate receptor encephaliti
researchProduct

Treatment of sudden sensorineural hearing loss with transtympanic injection of steroids as single therapy: a randomized clinical study.

2011

The aim of this study was to verify the efficacy and the safety of transtympanic dexamethasone to treat sudden sensorineural hearing loss as first and single drug method. Considering ethical implication of performing a mininvasive procedure on middle ear, we matched such proposed treatment with systemic prednisone administration that represents the widest adopted protocol. Randomized prospective study was conducted. The inclusion criterion was a sudden sensorineural hearing loss of at least 30 dB across three contiguous frequencies over a period of 24 h. Group A received transtympanic steroid injections; Group B received oral administration of steroids. 25 patients were treated with transty…

AdultMalemedicine.medical_specialtyTympanic MembraneHearing Loss SensorineuralAdministration OralInjections IntralesionalRisk AssessmentSeverity of Illness IndexDexamethasoneDrug Administration ScheduleAudiometryOral administrationPrednisoneSeverity of illnessmedicineHumansProspective StudiesProspective cohort studyDexamethasoneAgedAnalysis of Variancemedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryGeneral MedicineHearing Loss SuddenMiddle AgedSurgeryCochlea Deafness Round window Sudden sensorineural hearing loss Steroid TranstympanicTreatment OutcomeOtorhinolaryngologyOtorhinolaryngologyFemaleNeurosurgeryAudiometrybusinessmedicine.drugFollow-Up Studies
researchProduct

Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis

2018

Autoimmune hepatitis (AIH) frequently affects women of childbearing age in whom the desire to have a family raises the question regarding the potential risks for the fetus and the mother. The information on AIH in pregnant patients is scarce.1 The aims of this study were (1) to identify the risk factors associated with flares in pregnant patients diagnosed with AIH, (2) to determine the course of AIH in patients with pregnancy-related flares, and (3) to describe the outcome of AIH diagnosed in the postpartum period.

AdultPediatricsmedicine.medical_specialtyAutoimmune hepatitisCohort Studies03 medical and health sciences0302 clinical medicinePregnancyimmune system diseasesAzathioprinemedicineHumansIn patientAspartate AminotransferasesGlucocorticoidsreproductive and urinary physiologyRetrospective StudiesPregnancyHepatologybusiness.industryPostpartum PeriodPregnancy OutcomeGastroenterologyAlanine TransaminaseHypertension Pregnancy-InducedSymptom Flare Upmedicine.diseasedigestive system diseasesAbortion SpontaneousPregnancy ComplicationsDiabetes GestationalHepatitis Autoimmune030220 oncology & carcinogenesisChildbearing agePrednisoneDrug Therapy CombinationFemale030211 gastroenterology & hepatologyPresentation (obstetrics)businessImmunosuppressive AgentsPostpartum periodClinical Gastroenterology and Hepatology
researchProduct

Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols

2020

PETHEMA, HOVON, PALG, GATLA cooperative groups.

MaleMultivariate analysisOverweightTOXICITYBody Mass Index0302 clinical medicineLeukemia Promyelocytic AcuteRecurrenceAcute promyelocytic leukemiaAntineoplastic Combined Chemotherapy ProtocolsDIFFERENTIATION SYNDROMEOutcomeAged 80 and overAIDA protocolMercaptopurineMortality rateIncidence (epidemiology)HematologyGeneral MedicineMiddle AgedPrognosisTreatment OutcomeVincristinePopulation Surveillance030220 oncology & carcinogenesisFemalemedicine.symptomUnderweightAdultmedicine.medical_specialtyAdolescentACUTE MYELOID-LEUKEMIADIAGNOSISYoung Adult03 medical and health sciencesInternal medicinemedicineAsparaginaseHumansObesityRisk factorAgedRESPONSE CRITERIAOVERWEIGHTbusiness.industrynutritional and metabolic diseasesANTHRACYCLINEmedicine.diseaseObesityRISK-ADAPTED TREATMENTMethotrexateTRANS-RETINOIC ACIDPrednisonebusinessBody mass index030215 immunologyEuropean Journal of Haematology
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Long-term observation of endocrine ophthalmopathy and retrospective appraisal of therapeutic measures.

1990

The course of endocrine ophthalmopathy was investigated on the basis of clinical and biochemical parameters and in relation to different therapeutic strategies. A retrospective appraisal was made of 297 patients (44 +/- 14 yr, 249 women) with inclusion of anamnestic and clinical data as well as the results of computer tomography. At the beginning of therapy, 253 patients were hyperthyroid, 36 were euthyroid and eight were hypothyroid. The HLA typing carried out in 89 patients showed the phenotypes B8 and DR3 in 32% and 42% of the cases, respectively. Raised microsomal antibodies were present in 56% of the patients and there were raised thyroglobulin antibodies in 19%. Sixty-three % of the p…

AdultMaleIntraocular pressuremedicine.medical_specialtyTime FactorsAdolescentEye DiseasesEndocrinology Diabetes and MetabolismEye diseasemedicine.medical_treatmentVision DisordersCyclosporinsEndocrine System DiseasesEyeAutoimmune DiseasesEndocrinologyImmunopathologyInternal medicinemedicineExophthalmosHumansEuthyroidEndocrine ophthalmopathyGlucocorticoidsIntraocular PressureVision OcularAgedRetrospective Studiesbusiness.industryMusclesRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryPrednisoneThyroglobulinFemalebusinessComplicationTomography X-Ray ComputedJournal of endocrinological investigation
researchProduct